The trading price of Provention Bio, Inc. (NASDAQ:PRVB) floating lower at last check on Wednesday, Jan 13, closing at $19.45, -10.54% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it has been fluctuating between $15.45 and $17.53. The company’s P/E ratio in the trailing 12-month period was 0, while its 5Y monthly beta was 0. In examining the 52-week price action we see that the stock hit a 52-week high of $20.05 and a 52-week low of $4.72. Over the past month, the stock has gained 11.4% in value.
Provention Bio, Inc., whose market valuation is $1.12 Billion at the time of this writing, is expected to release its quarterly earnings report in Feb 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.5 per share this quarter, however they have predicted annual earnings per share of -$1.78 for 2021 and -$2.1 for 2022. It means analysts are expecting annual earnings per share growth of 0.68% this year and 0.18% next year.
On the technical side, indicators suggest PRVB has a 50% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned PRVB a recommendation rating is 7. Out of them, no one rate it a Hold, while 6 recommend Buy, whereas 1 assign an Outperform rating. None analyst(s) have tagged Provention Bio, Inc. (PRVB) as Underperform, while not any of them advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 0, which symbolizes a positive outlook. A quick review shows that PRVB’s price is currently -2.82% off the SMA20 and 8.13% off the SMA50. The RSI metric on the 14-day chart is currently showing 50.47, and weekly volatility stands at 6.37%. When measured over the past 30 days, the indicator reaches 5.74%. Provention Bio, Inc. (NASDAQ:PRVB)’s beta value is currently sitting at 0, while the Average True Range indicator is currently displaying 1.04. With analysts defining $25-$40 as the low and high price targets, we arrive at a consensus price target of $29 for the trailing 12-month period. The current price is about 43.68% off the estimated low and 129.89% off the forecast high, based on this estimate. Investors will be thrilled if PRVB’s share price rises to $27, which is the median consensus price. At that level, PRVB’s share price would be +55.17% above current price.
To see how Provention Bio, Inc. stock has been performing today in comparison to its peers in the industry, here are the numbers: PRVB stock’s performance was -10.54% at last check in today’s session, and +23.1% in the past year, while Bristol-Myers Squibb Company (BMY) has been trading -0.6% in recent session and positioned -1.09% lower than it was a year ago. Another comparable company Amgen Inc (AMGN) saw its stock trading 0.12% higher in today’s session but was down -0.14% in a year. Furthermore, Gilead Sciences Inc (GILD) showed a decline of -10.54% today while its price kept rising at 23.1% over the past year. Provention Bio, Inc. has a P/E ratio of 0, compared to Bristol-Myers Squibb Company’s 0 and Amgen Inc’s 19.08. Also during today’s trading, the S&P 500 Index has surged 0.11%, while the Dow Jones Industrial also saw a negative seesion, down -0.1% today.
An evaluation of the daily trading volume of Provention Bio, Inc. (NASDAQ:PRVB) indicates that the 3-month average is 514.93 Million. However, this figure has increased over the past 10 days to an average of 640.14 Million.
Currently, records show that 56.49 Million of the company’s shares remain outstanding. According to Thomson Reuters data, insiders hold 18.25% of outstanding shares, whereas institutions hold 42.81%. The stats also highlight that short interest as of December 14, 2020, stood at 3.29 Million shares, resulting in a short ratio of 5.77 at that time. From this, we can conclude that short interest is 5.82% of the company’s total outstanding shares. It is noteworthy that short shares in December were down slightly from the previous month’s figure, which was 3.47 Million. However, since the stock’s price has seen +14.82% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
Even if you’re not actively in crypto, you deserve to know what’s actually going on..
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.